Comprehensive Stock Comparison
Compare Arcus Biosciences, Inc. (RCUS) vs Merus N.V. (MRUS) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | RCUS | -4.3% revenue growth vs MRUS's -12.4% |
| Quality / Margins | RCUS | -142.9% net margin vs MRUS's -6.5% |
| Stability / Safety | MRUS | Beta 0.90 vs RCUS's 1.37, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | MRUS | +91.1% vs RCUS's +87.1% |
| Efficiency (ROA) | RCUS | -31.0% ROA vs MRUS's -43.4%, ROIC -64.1% vs -74.6% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Arcus Biosciences is a clinical-stage biopharmaceutical company developing novel cancer immunotherapies targeting multiple pathways in the tumor microenvironment. It generates revenue primarily through research funding and milestone payments from collaboration partners — notably Gilead Sciences — with potential future earnings from drug sales if its pipeline candidates gain regulatory approval. The company's competitive advantage lies in its differentiated portfolio targeting complementary immuno-oncology mechanisms and its strategic partnerships that provide both funding and development expertise.
Merus N.V. is a clinical-stage biotechnology company developing bispecific antibody therapies for cancer treatment. It generates revenue primarily through research collaborations and licensing deals — with no commercial products yet — while advancing its pipeline through clinical trials. The company's competitive advantage lies in its proprietary antibody discovery platform that enables the creation of novel bispecific antibodies targeting multiple cancer pathways simultaneously.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
MRUS leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). RCUS leads in 2 (Financial Metrics, Valuation Metrics).
Financial Metrics (TTM)
RCUS is the larger business by revenue, generating $247M annually — 4.8x MRUS's $51M. Profitability is closely matched — net margins range from -142.9% (RCUS) to -6.5% (MRUS). On growth, RCUS holds the edge at +26.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | RCUSArcus Biosciences… | MRUSMerus N.V. |
|---|---|---|
| RevenueTrailing 12 months | $247M | $51M |
| EBITDAEarnings before interest/tax | -$386M | -$329M |
| Net IncomeAfter-tax profit | -$353M | -$335M |
| Free Cash FlowCash after capex | -$484M | -$318M |
| Gross MarginGross profit ÷ Revenue | — | -2.2% |
| Operating MarginEBIT ÷ Revenue | -156.3% | -6.5% |
| Net MarginNet income ÷ Revenue | -142.9% | -6.5% |
| FCF MarginFCF ÷ Revenue | -196.0% | -6.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +26.9% | -1.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +10.3% | +13.7% |
Valuation Metrics
| Metric | RCUSArcus Biosciences… | MRUSMerus N.V. |
|---|---|---|
| Market CapShares × price | $2.6B | $6.8B |
| Enterprise ValueMkt cap + debt − cash | $2.4B | $6.5B |
| Trailing P/EPrice ÷ TTM EPS | -6.19x | -26.87x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 10.33x | 195.71x |
| Price / BookPrice ÷ Book value/share | 3.47x | 8.92x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
MRUS delivers a -50.6% return on equity — every $100 of shareholder capital generates $-51 in annual profit, vs $-56 for RCUS. MRUS carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to RCUS's 0.16x. On the Piotroski fundamental quality scale (0–9), MRUS scores 4/9 vs RCUS's 0/9, reflecting mixed financial health.
| Metric | RCUSArcus Biosciences… | MRUSMerus N.V. |
|---|---|---|
| ROE (TTM)Return on equity | -55.9% | -50.6% |
| ROA (TTM)Return on assets | -31.0% | -43.4% |
| ROICReturn on invested capital | -64.1% | -74.6% |
| ROCEReturn on capital employed | -42.1% | -48.4% |
| Piotroski ScoreFundamental quality 0–9 | 0 | 4 |
| Debt / EquityFinancial leverage | 0.16x | 0.02x |
| Net DebtTotal debt minus cash | -$123M | -$283M |
| Cash & Equiv.Liquid assets | $222M | $293M |
| Total DebtShort + long-term debt | $99M | $10M |
| Interest CoverageEBIT ÷ Interest expense | — | — |
Total Returns (with DRIP)
A $10,000 investment in MRUS five years ago would be worth $37,768 today (with dividends reinvested), compared to $5,549 for RCUS. Over the past 12 months, MRUS leads with a +91.1% total return vs RCUS's +87.1%. The 3-year compound annual growth rate (CAGR) favors MRUS at 67.7% vs RCUS's 3.8% — a key indicator of consistent wealth creation.
| Metric | RCUSArcus Biosciences… | MRUSMerus N.V. |
|---|---|---|
| YTD ReturnYear-to-date | -12.5% | 0.0% |
| 1-Year ReturnPast 12 months | +87.1% | +91.1% |
| 3-Year ReturnCumulative with dividends | +11.9% | +371.9% |
| 5-Year ReturnCumulative with dividends | -44.5% | +277.7% |
| 10-Year ReturnCumulative with dividends | +19.8% | +796.4% |
| CAGR (3Y)Annualised 3-year return | +3.8% | +67.7% |
Risk & Volatility
MRUS is the less volatile stock with a 0.90 beta — it tends to amplify market swings less than RCUS's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MRUS currently trades 92.6% from its 52-week high vs RCUS's 77.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RCUSArcus Biosciences… | MRUSMerus N.V. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.37x | 0.90x |
| 52-Week HighHighest price in past year | $26.40 | $97.14 |
| 52-Week LowLowest price in past year | $6.50 | $33.19 |
| % of 52W HighCurrent price vs 52-week peak | +77.2% | +92.6% |
| RSI (14)Momentum oscillator 0–100 | 43.5 | 14.9 |
| Avg Volume (50D)Average daily shares traded | 997K | 520K |
Analyst Outlook
Wall Street rates RCUS as "Buy" and MRUS as "Hold". Consensus price targets imply 37.5% upside for RCUS (target: $28) vs 7.8% for MRUS (target: $97).
| Metric | RCUSArcus Biosciences… | MRUSMerus N.V. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold |
| Price TargetConsensus 12-month target | $28.00 | $97.00 |
| # AnalystsCovering analysts | 17 | 22 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Arcus Biosciences, … (RCUS) | 100 | 123.14 | +23.1% |
| Merus N.V. (MRUS) | 100 | 511.95 | +411.9% |
Merus N.V. (MRUS) returned +278% over 5 years vs Arcus Biosciences, … (RCUS)'s -45%. A $10,000 investment in MRUS 5 years ago would be worth $37,768 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Arcus Biosciences, … (RCUS) | $0.00 | $247M | — |
| Merus N.V. (MRUS) | $3M | $35M | +1289.6% |
Arcus Biosciences, Inc.'s revenue grew from $0M (2016) to $247M (2025) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Arcus Biosciences, … (RCUS) | -37.6% | -142.9% | -280.4% |
| Merus N.V. (MRUS) | -18.9% | -6.0% | +68.5% |
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Arcus Biosciences, … (RCUS) | -0.73 | -3.29 | -350.7% |
| Merus N.V. (MRUS) | -3.75 | -3.35 | +10.7% |
Arcus Biosciences, Inc.'s EPS grew from $-0.73 (2016) to $-3.29 (2025).
Chart 5Free Cash Flow — 5 Years
Arcus Biosciences, Inc. generated $-484M FCF in 2025 (-71% vs 2021). Merus N.V. generated $-188M FCF in 2024 (-210% vs 2021).
RCUS vs MRUS: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is RCUS or MRUS a better buy right now?
Analysts rate Arcus Biosciences, Inc. (RCUS) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RCUS or MRUS?
Over the past 5 years, Merus N.V. (MRUS) delivered a total return of +277.7%, compared to -44.5% for Arcus Biosciences, Inc. (RCUS). A $10,000 investment in MRUS five years ago would be worth approximately $38K today (assuming dividends reinvested). Over 10 years, the gap is even starker: MRUS returned +796.4% versus RCUS's +19.8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RCUS or MRUS?
By beta (market sensitivity over 5 years), Merus N.V. (MRUS) is the lower-risk stock at 0.90β versus Arcus Biosciences, Inc.'s 1.37β — meaning RCUS is approximately 51% more volatile than MRUS relative to the S&P 500. On balance sheet safety, Merus N.V. (MRUS) carries a lower debt/equity ratio of 2% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — RCUS or MRUS?
Arcus Biosciences, Inc. (RCUS) is the more profitable company, earning -142.9% net margin versus -595.9% for Merus N.V. — meaning it keeps -142.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RCUS leads at -156.3% versus -753.0% for MRUS. At the gross margin level — before operating expenses — MRUS leads at 37.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — RCUS or MRUS?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is RCUS or MRUS better for a retirement portfolio?
For long-horizon retirement investors, Merus N.V. (MRUS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.90), +796.4% 10Y return). Both have compounded well over 10 years (MRUS: +796.4%, RCUS: +19.8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between RCUS and MRUS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.